Alexey Surov1, Jin You Kim2, Marco Aiello3, Wei Huang4, Thomas E Yankeelov5, Andreas Wienke6, Maciej Pech7. 1. Department of Radiology and Nuclear Medicine, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany; Alexey.Surov@med.ovgu.de. 2. Medical Research Institute and Department of Radiology, Pusan National University School of Medicine, Busan, Republic of Korea. 3. RCCS SDN, Istituto di Ricerca, Naples, Italy. 4. Advanced Imaging Research Center, Oregon Health & Science University, Portland, OR, U.S.A. 5. Institute of Imaging Science, Vanderbilt University, Nashville, TN, U.S.A. 6. Institute of Medical Epidemiology, Biostatistics, and Informatics, Martin-Luther-University Halle-Wittenberg, Halle, Germany. 7. Department of Radiology and Nuclear Medicine, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany.
Abstract
BACKGROUND/AIM: To provide data regarding relationships between quantitative dynamic contrast enhanced magnetic resonance imaging (DCE MRI) and prognostic factors in breast cancer (BC). PATIENTS AND METHODS: Data from 4 Centers (200 female patients, mean age, 51.2±11.5 years) were acquired. The following data were collected: histopathological diagnosis, tumor grade, stage, hormone receptor status, KI 67, and DCE MRI values including Ktrans (volume transfer constant), Ve (volume of the extravascular extracellular leakage space (EES) and Kep (diffusion of contrast medium from the EES back to the plasma). DCE MRI values between different groups were compared using the Mann-Whitney U-test and by the Kruskal-Wallis H test. The association between DCE MRI and Ki 67 values was calculated by the Spearman's rank correlation coefficient. RESULTS: DCE MRI values of different tumor subtypes overlapped significantly. There were no statistically significant differences of DCE MRI values between different tumor grades. All DCE MRI parameters correlated with KI-67: Ktrans, r=0.44, p=0.0001; Ve, r=0.34, p=0.0001; Kep, r=0.28, p=0.002. ROC analysis identified a Ktrans threshold of 0.3 min-1 for discrimination of tumors with low KI-67 expression (<25%) and high KI-67 expression (≥25%): sensitivity, 75.5%, specificity, 73.0%, accuracy, 74.0%, AUC, 0.78. DCE MRI values overlapped between tumors with different T and N stages. CONCLUSION: Ktrans, Kep, and Ve cannot be used as reliable a surrogate marker for hormone receptor status, tumor stage and grade in BC. Ktrans may discriminate lesions with high and lower proliferation activity.
BACKGROUND/AIM: To provide data regarding relationships between quantitative dynamic contrast enhanced magnetic resonance imaging (DCE MRI) and prognostic factors in breast cancer (BC). PATIENTS AND METHODS: Data from 4 Centers (200 female patients, mean age, 51.2±11.5 years) were acquired. The following data were collected: histopathological diagnosis, tumor grade, stage, hormone receptor status, KI 67, and DCE MRI values including Ktrans (volume transfer constant), Ve (volume of the extravascular extracellular leakage space (EES) and Kep (diffusion of contrast medium from the EES back to the plasma). DCE MRI values between different groups were compared using the Mann-Whitney U-test and by the Kruskal-Wallis H test. The association between DCE MRI and Ki 67 values was calculated by the Spearman's rank correlation coefficient. RESULTS: DCE MRI values of different tumor subtypes overlapped significantly. There were no statistically significant differences of DCE MRI values between different tumor grades. All DCE MRI parameters correlated with KI-67: Ktrans, r=0.44, p=0.0001; Ve, r=0.34, p=0.0001; Kep, r=0.28, p=0.002. ROC analysis identified a Ktrans threshold of 0.3 min-1 for discrimination of tumors with low KI-67 expression (<25%) and high KI-67 expression (≥25%): sensitivity, 75.5%, specificity, 73.0%, accuracy, 74.0%, AUC, 0.78. DCE MRI values overlapped between tumors with different T and N stages. CONCLUSION: Ktrans, Kep, and Ve cannot be used as reliable a surrogate marker for hormone receptor status, tumor stage and grade in BC. Ktrans may discriminate lesions with high and lower proliferation activity.
Authors: Jia Shen Jiang; Ye Hua; Xue Jun Zhou; Dan Dan Shen; Jin Long Shi; Min Ge; Qi Nan Geng; Zhong Zheng Jia Journal: Acad Radiol Date: 2018-11-08 Impact factor: 3.173
Authors: Alexey Surov; Hans Jonas Meyer; Matthias Gawlitza; Anne-Kathrin Höhn; Andreas Boehm; Thomas Kahn; Patrick Stumpp Journal: Transl Oncol Date: 2016-11-24 Impact factor: 4.243
Authors: Alexey Surov; Yun-Woo Chang; Lihua Li; Laura Martincich; Savannah C Partridge; Jin You Kim; Andreas Wienke Journal: BMC Cancer Date: 2019-11-05 Impact factor: 4.430